See the DrugPatentWatch profile for sprycel
What Conditions Is Sprycel Approved For?
Sprycel (dasatinib) treats specific types of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). It is FDA-approved for:
- Adults with Philadelphia chromosome-positive (Ph+) CML in chronic phase resistant or intolerant to prior therapy like imatinib.
- Adults with accelerated or myeloid/blast phase Ph+ CML with resistance or intolerance to prior therapy.
- Adults and children 1 year and older with Ph+ ALL resistant or intolerant to prior therapy.[1]
It targets BCR-ABL tyrosine kinase to block cancer cell growth in these blood cancers.
Is Sprycel Used for All Types of Leukemia?
No. Sprycel is not approved or routinely used for all leukemias. It works only for Ph+ subtypes of CML and ALL, which involve a specific genetic abnormality (Philadelphia chromosome from BCR-ABL fusion). Common leukemias like acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), or Ph-negative ALL do not respond to it.[1][2]
How Does Sprycel Compare to Other Leukemia Treatments?
Sprycel is a second-generation tyrosine kinase inhibitor (TKI), more potent than first-line Gleevec (imatinib) for resistant cases. Alternatives include:
- Imatinib or nilotinib for newly diagnosed Ph+ CML.
- Ponatinib for heavily resistant cases.
- Chemotherapy or stem cell transplant for Ph-negative leukemias.
Off-label use in non-Ph+ leukemias is rare and lacks strong evidence.[2]
| Drug | Primary Use | Key Difference from Sprycel |
|------|-------------|-----------------------------|
| Gleevec (imatinib) | First-line Ph+ CML/ALL | Less effective in resistant cases; Sprycel often follows it. |
| Tasigna (nilotinib) | Ph+ CML chronic phase | Similar potency; chosen based on side effect profile. |
| Iclusig (ponatinib) | Resistant Ph+ CML/ALL | Stronger for T315I mutations but higher vascular risks. |
What If Someone Has a Different Type of Leukemia?
Sprycel provides no benefit for non-Ph+ leukemias. Testing for Philadelphia chromosome status is standard before starting TKIs. Misuse risks side effects like pleural effusion, pulmonary hypertension, or myelosuppression without tumor control.[1]
Common Patient Questions on Sprycel Use
- Who cannot take it? Avoid in pregnancy (embryotoxic), uncontrolled heart issues, or with strong CYP3A4 drugs.
- How long is treatment? Often lifelong for CML if responding.
- Patent status? Key U.S. patents expired in 2025; generics may enter soon. Check DrugPatentWatch.com for updates.[3]
[1] Sprycel Prescribing Information, Bristol Myers Squibb (FDA label, last updated 2023).
[2] National Comprehensive Cancer Network (NCCN) Guidelines for CML and ALL, Version 2024.
[3] DrugPatentWatch.com, Dasatinib patent database (accessed 2024).